Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedFeb 15, 2026
DataAggregated Company Financials
Companies317
  • 7D-0.4%
  • 3M13.3%
  • 1Y32.0%
  • YTD5.9%

Over the last 7 days, the Pharma industry has remained flat. The past year has been better, since the industry has gained 32% in that time. As for the next few years, earnings are expected to grow by 11% per annum.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 16 Feb 2026US$2.4tUS$411.4bUS$73.9b20.2x32.3x5.8x
Wed, 14 Jan 2026US$2.3tUS$402.6bUS$71.5b20.5x32x5.7x
Fri, 12 Dec 2025US$2.1tUS$402.8bUS$71.4b19.9x30.1x5.3x
Sun, 09 Nov 2025US$2.0tUS$396.3bUS$70.8b17.9x27.7x4.9x
Tue, 07 Oct 2025US$1.9tUS$387.9bUS$60.9b19.2x31.7x5x
Thu, 04 Sep 2025US$1.8tUS$387.9bUS$61.0b19.5x29.2x4.6x
Sat, 02 Aug 2025US$1.7tUS$381.9bUS$55.1b17.8x30.7x4.4x
Mon, 30 Jun 2025US$1.7tUS$382.7bUS$61.2b17.5x27.9x4.5x
Wed, 28 May 2025US$1.6tUS$382.6bUS$61.2b17.5x26.9x4.3x
Fri, 25 Apr 2025US$1.7tUS$380.6bUS$48.4b16.1x35.9x4.6x
Sun, 23 Mar 2025US$1.9tUS$381.1bUS$41.3b17x45.6x4.9x
Tue, 18 Feb 2025US$1.8tUS$380.9bUS$39.0b18.1x46.9x4.8x
Thu, 16 Jan 2025US$1.8tUS$369.3bUS$31.2b18.5x56.4x4.8x
Sat, 14 Dec 2024US$1.8tUS$373.8bUS$30.6b18.4x59.1x4.8x
Mon, 11 Nov 2024US$1.9tUS$373.7bUS$30.3b21.4x62.8x5.1x
Wed, 09 Oct 2024US$2.0tUS$364.1bUS$25.2b18.2x78.7x5.5x
Fri, 06 Sep 2024US$2.1tUS$364.1bUS$25.5b17.9x80.7x5.6x
Sun, 04 Aug 2024US$1.9tUS$359.3bUS$22.1b15.8x86.8x5.3x
Tue, 02 Jul 2024US$1.9tUS$357.6bUS$13.8b16x140.9x5.4x
Thu, 30 May 2024US$1.9tUS$358.3bUS$14.1b15.8x132x5.2x
Sat, 27 Apr 2024US$1.8tUS$359.5bUS$17.5b22.4x102.8x5x
Mon, 25 Mar 2024US$1.9tUS$355.3bUS$22.6b19.8x82.6x5.3x
Wed, 21 Feb 2024US$1.9tUS$355.0bUS$23.9b28.5x78.6x5.3x
Fri, 19 Jan 2024US$1.7tUS$375.2bUS$33.9b27.7x51.6x4.7x
Sun, 17 Dec 2023US$1.6tUS$375.1bUS$33.9b26.7x48.6x4.4x
Tue, 14 Nov 2023US$1.6tUS$375.5bUS$34.1b26.5x48x4.4x
Thu, 12 Oct 2023US$1.7tUS$381.8bUS$43.8b17.1x39x4.5x
Sat, 09 Sep 2023US$1.8tUS$381.8bUS$43.9b19.1x41.3x4.7x
Mon, 07 Aug 2023US$1.7tUS$379.8bUS$43.1b20.5x39.1x4.4x
Wed, 05 Jul 2023US$1.7tUS$392.8bUS$60.2b18.6x29x4.4x
Fri, 02 Jun 2023US$1.7tUS$393.0bUS$60.5b18.3x27.9x4.3x
Sun, 30 Apr 2023US$1.7tUS$400.2bUS$62.2b17.4x27x4.2x
Tue, 28 Mar 2023US$1.6tUS$401.2bUS$69.5b14.7x22.5x3.9x
Thu, 23 Feb 2023US$1.6tUS$401.7bUS$68.5b17.6x23.6x4x
Price to Earnings Ratio

23.6x


Total Market Cap: US$1.6tTotal Earnings: US$68.5bTotal Revenue: US$401.7bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 53.2x202420252026
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 32.3x which is lower than its 3-year average PE of 53.2x.
  • The 3-year average PS ratio of 4.8x is lower than the industry's current PS ratio of 5.8x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 2.6% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-1.34%
Healthcare-1.06%
Pharma-0.38%
Pharma-0.38%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
JNJ Johnson & JohnsonUS$243.451.4%
+US$8.5b		55.9%PE21.9x
PFE PfizerUS$27.581.3%
+US$2.0b		8.0%PE20.2x
RGC Regencell Bioscience HoldingsUS$31.2214.7%
+US$2.0b		31,536.3%PB3176.4x
VTRS ViatrisUS$15.778.2%
+US$1.4b		46.0%PS1.3x
NKTR Nektar TherapeuticsUS$71.3393.8%
+US$1.2b		384.0%PS31.9x

Latest News

JNJ
US$243.45
Johnson & Johnson
7D
1.4%
1Y
55.9%
ZTS
US$126.65
Zoetis
7D
-0.6%
1Y
-19.6%
RPRX
US$45.19
Royalty Pharma
7D
1.2%
1Y
39.6%
MRK
US$121.41
Merck
7D
-0.4%
1Y
46.3%
NKTR
US$71.33
Nektar Therapeutics
7D
93.8%
1Y
384.0%

Nektar Therapeutics' (NASDAQ:NKTR) Shares Climb 81% But Its Business Is Yet to Catch Up

Feb 12
Nektar Therapeutics' (NASDAQ:NKTR) Shares Climb 81% But Its Business Is Yet to Catch Up
VTRS
US$15.77
Viatris
7D
8.2%
1Y
46.0%
MANE
US$43.46
Veradermics
7D
12.9%
1Y
n/a
LLY
US$1,040.00
Eli Lilly
7D
-1.7%
1Y
23.2%

LLY: Government Pricing Deals Will Compress Obesity Franchise Economics Going Forward

Analysts have raised their fair value estimate for Eli Lilly from US$770 to about US$884 per share, reflecting updated assumptions on long term obesity opportunities, recent price target increases across several firms, and steady expectations around margins and future P/E multiples. Analyst Commentary The latest batch of research on Eli Lilly revolves around its weight loss and cardiometabolic franchises, expectations for new product launches, and the implications of recent policy developments on pricing and access.
PFE
US$27.58
Pfizer
7D
1.3%
1Y
8.0%

PFE: Obesity Pipeline And LOE Headwinds Will Shape Future Re Rating

Narrative Update Analysts have trimmed their fair value estimate for Pfizer from $36.16 to $35.46, reflecting more cautious assumptions on revenue trends and profit margins, even as some on the Street highlight new assets and deals that they believe could support a higher future P/E multiple. Analyst Commentary Recent Street research on Pfizer highlights a mix of caution and optimism, with several firms reassessing how the pipeline and recent deals might offset upcoming patent expiries and support the valuation over time.
BMY
US$60.74
Bristol-Myers Squibb
7D
-2.0%
1Y
12.7%

BMY: 2026 Pipeline Readouts And Sector Recovery Will Guide Next Repricing

Our analyst fair value estimate for Bristol Myers Squibb has moved modestly higher to US$58.13 from US$56.26. This reflects updated Street research in which analysts cite a richer mix of potential 2026 pipeline catalysts and a slightly higher assumed future P/E multiple, both of which support recent price target increases across several firms.
TEVA
US$33.98
Teva Pharmaceutical Industries
7D
-2.0%
1Y
109.1%

TEVA: Affordable Medicines And 2026 Pipeline Milestones Will Shape Medium Term Outlook

Analysts have raised their price targets on Teva Pharmaceutical Industries into a tighter valuation range, with our fair value estimate moving from US$35.32 to US$36.77. They point to improving profit margin assumptions, a lower future P/E, and support from recent research highlighting the affordable medicines theme and potential pipeline catalysts into 2026.
BLTE
US$175.26
Belite Bio
7D
-6.7%
1Y
213.0%
LQDA
US$38.20
Liquidia
7D
-11.2%
1Y
135.8%
NMRA
US$3.20
Neumora Therapeutics
7D
50.9%
1Y
83.9%
RGC
US$31.22
Regencell Bioscience Holdings
7D
14.7%
1Y
31,536.3%
GPCR
US$70.07
Structure Therapeutics
7D
-6.5%
1Y
187.3%